Retatrutide 36mg

Retatrutide 36 mg – Triple Agonist Peptide for Advanced Metabolic Research

Retatrutide 36 mg is a high-purity, research-grade peptide designed to act as a triple hormone receptor agonist, targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This potent 36 mg formulation offers a comprehensive tool for investigating the complex hormonal regulation of body weight, glucose metabolism, and energy homeostasis.

Retatrutide 36mg, By engaging multiple metabolic pathways simultaneously, Retatrutide supports advanced preclinical studies focused on:

• Obesity and weight loss mechanisms

• Type 2 diabetes and insulin resistance

• Appetite suppression and satiety signaling

• Fat oxidation and energy expenditure

Key Features: Retatrutide 36mg

• High-dose 36 mg format for extended and high-volume research protocols

• Triple agonist activity offering superior metabolic effects over single-pathway agents

• Lyophilized powder for long-term stability and flexible dosing

• Synthesized to a purity of ≥98% (HPLC verified)

• Suitable for in vivo and in vitro metabolic research models

Product Details:

• Name: Retatrutide

• Form: Lyophilized peptide

• Purity: ≥98%

• Dosage: 36 mg per vial

• Molecular Formula: C₁₈₇H₂₉₄N₅₄O₅₉

• Storage: -20°C, protect from light and moisture

• Reconstitution: Sterile water or appropriate buffer

Applications:

• Mechanistic studies in obesity, diabetes, and metabolic syndrome

• Exploration of multi-agonist therapeutics

• Metabolic rate, food intake, and glucose utilization experiments

• Preclinical dose-response and pharmacokinetic assessments.